NYSEAMERICAN:AST

Asterias Biotherapeutics Stock Forecast, Price & News

$0.94
-0.01 (-1.05 %)
(As of 12/31/1969)
Add
Compare
Today's Range
$0.90
▼
$0.95
50-Day Range N/A
52-Week Range
$0.51
▼
$2.05
Volume99,200 shs
Average Volume136,653 shs
Market Capitalization$52.32 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
30 days | 90 days | 365 days | Advanced Chart
Receive AST News and Ratings via Email

Sign-up to receive the latest news and ratings for Asterias Biotherapeutics and its competitors with MarketBeat's FREE daily newsletter.


Asterias Biotherapeutics logo

About Asterias Biotherapeutics

Asterias Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing cell-based therapeutics to treat neurological conditions associated with demyelination, and cellular immunotherapies to treat cancer. Its clinical stage programs include AST-OPC1, an oligodendrocyte progenitor cell population derived from pluripotent stem cells that is in Phase I/IIa clinical trial for spinal cord injuries; AST-VAC2 is a non-patient-specific cancer immunotherapy derived from pluripotent stem cells for the treatment of non-small cell lung cancer; and AST-VAC1, a patient-specific cancer immunotherapy that has completed Phase II clinical trial for the treatment of acute myeloid leukemia. The company was formerly known as BioTime Acquisition Corporation and changed its name to Asterias Biotherapeutics, Inc. in March 2013. Asterias Biotherapeutics, Inc. was founded in 2012 and is headquartered in Fremont, California.

Headlines

Spinal Cord Trauma Treatment Market 2027 | Trends, Growth Overview, Development Size and Revenue Forecast | ARC
Spinal Cord Trauma Treatment Market 2027 | Trends, Growth Overview, Development Size and Revenue Forecast | ARC
June 2, 2021 |  marketwatch.com
Geron Corporation Reports First Quarter 2021 Financial Results and Recent Highlights
Geron Corporation Reports First Quarter 2021 Financial Results and Recent Highlights
May 10, 2021 |  ca.finance.yahoo.com
Spinal cord trauma treatment market is expected to reach the market value of around US$ 4,547.2 Mn by 2027. | ARC
Spinal cord trauma treatment market is expected to reach the market value of around US$ 4,547.2 Mn by 2027. | ARC
April 30, 2021 |  marketwatch.com
Global Lung Cancer Therapies Market Will Generate All New Growth Opportunities During Coronavirus Pandemic Period (2021-2027)
Global Lung Cancer Therapies Market Will Generate All New Growth Opportunities During Coronavirus Pandemic Period (2021-2027)
April 21, 2021 |  marketwatch.com
Spinal Cord Trauma Treatment Market Value Anticipated To Reach US$ 4,547.2 Million By 2027: Acumen Research And Consulting
Spinal Cord Trauma Treatment Market Value Anticipated To Reach US$ 4,547.2 Million By 2027: Acumen Research And Consulting
February 9, 2021 |  benzinga.com
Spinal Cord Trauma Treatment Market 2021 : Top countries Data, Market Size, In-Depth Analysis with Booming Trends and Segmentation Forecast to 2026
Spinal Cord Trauma Treatment Market 2021 : Top countries Data, Market Size, In-Depth Analysis with Booming Trends and Segmentation Forecast to 2026
February 2, 2021 |  marketwatch.com
Global Spinal Cord Injury Therapeutics Market to Surpass US$ 9,239.1 Million by 2027, Says Coherent Market Insights (CMI)
Global Spinal Cord Injury Therapeutics Market to Surpass US$ 9,239.1 Million by 2027, Says Coherent Market Insights (CMI)
December 18, 2020 |  benzinga.com
Geron Corporation Reports Third Quarter 2020 Financial Results and Current Events | Benzinga
Geron Corporation Reports Third Quarter 2020 Financial Results and Current Events | Benzinga
November 7, 2020 |  benzinga.com
Prop. 14: Stem cells measure passing in early returns
Prop. 14: Stem cells measure passing in early returns
November 4, 2020 |  msn.com
Superior Uniform Group (SGC)
Superior Uniform Group (SGC)
October 30, 2020 |  forbes.com
See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank™

Overall MarketRank™

0.52 out of 5 stars

Medical Sector

1592nd out of 2,099 stocks

Biotechnology Industry

41st out of 88 stocks

Analyst Opinion: 0.0Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Asterias Biotherapeutics (NYSEAMERICAN:AST) Frequently Asked Questions

What stocks does MarketBeat like better than Asterias Biotherapeutics?

Wall Street analysts have given Asterias Biotherapeutics a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Asterias Biotherapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

How were Asterias Biotherapeutics' earnings last quarter?

Asterias Biotherapeutics Inc (NYSEAMERICAN:AST) released its earnings results on Tuesday, March, 28th. The biotechnology company reported ($0.18) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.17) by $0.01. The biotechnology company earned $1.75 million during the quarter, compared to the consensus estimate of $2.81 million.
View Asterias Biotherapeutics' earnings history.

Who are Asterias Biotherapeutics' key executives?

Asterias Biotherapeutics' management team includes the following people:
  • Mr. Michael H. Mulroy, CEO, Pres & Director (Age 53)
  • Dr. Edward D. Wirth III, Chief Medical Officer (Age 54)
  • Dr. Katharine E. Spink, Consultant (Age 45)
  • Mr. Stephen L. Cartt, Advisor & Director (Age 56)
  • Mr. Ryan D. Chavez, CFO & Gen. Counsel (Age 43)

Who are some of Asterias Biotherapeutics' key competitors?

Some companies that are related to Asterias Biotherapeutics include (CHV) (CHV), (DDXS) (DDXS), (PREV) (PREV), (TNGN) (TNGN), 138267 (COM.TO) (COM), Abattis Bioceuticals (ATTBF), Abzena (ABZA), Acrux (ACR), Actinogen Medical (ACW), AdAlta (1AD), Admedus (AHZ), Algernon Pharmaceuticals (AGNPF), Almirall (LBTSF), Amarantus BioScience (AMBS) and Amplia Therapeutics (ATX).
View all of AST's competitors.

What other stocks do shareholders of Asterias Biotherapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Asterias Biotherapeutics investors own include Brooklyn ImmunoTherapeutics (BTX), Zynerba Pharmaceuticals (ZYNE), Synergy Pharmaceuticals (SGYP), CorMedix (CRMD), Progenics Pharmaceuticals (PGNX), Sangamo Therapeutics (SGMO), 22nd Century Group (XXII), Amarin (AMRN), Anavex Life Sciences (AVXL) and Freeport-McMoRan (FCX).

What is Asterias Biotherapeutics' stock symbol?

Asterias Biotherapeutics trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "AST."

How do I buy shares of Asterias Biotherapeutics?

Shares of AST can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Asterias Biotherapeutics' stock price today?

One share of AST stock can currently be purchased for approximately $0.94.

How much money does Asterias Biotherapeutics make?

Asterias Biotherapeutics has a market capitalization of $52.32 million.

What is Asterias Biotherapeutics' official website?

The official website for Asterias Biotherapeutics is asteriasbiotherapeutics.com.

Where are Asterias Biotherapeutics' headquarters?

Asterias Biotherapeutics is headquartered at 6300 Dumbarton Cir, FREMONT, CA 94555-3644, United States.

How can I contact Asterias Biotherapeutics?

Asterias Biotherapeutics' mailing address is 6300 Dumbarton Cir, FREMONT, CA 94555-3644, United States. The biotechnology company can be reached via phone at +1-510-4563805.


This page was last updated on 6/14/2021 by MarketBeat.com Staff

As Featured By:

MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.